IT Transformation and Cloud Content Management for MedTech, Biotechnology and Pharmaceutical Companies

INconnect28 - 29 September 2017, Berlin, Germany.
Due to evolving technology and accelerated growth in research and development activities, cloud computing and IT business technology have increased rapidly. Over the past decades, cloud computing has had profound impact in Life Sciences industry by bringing efficiencies, allowing enterprise-wide agility, and boosting patient outcomes. Cloud computing solutions has reshaped promotional strategies of various Life Science companies and transformed modes of interactions with physicians.

As Life Science sector is currently improving and accelerating its correlation with IT, the Life Sciences Cloud Coalition have moved to the cloud computing and working with their patient through it.

Global Cloud Computing in Life Science Market is expected to expand at a rapid pace during the period of 2015 - 2023 due to the increasing use of cloud computing in Life Science research and development.

This event will serve as a business networking platform as well as a scientific examination of the advantages and disadvantages in implementing IT modernization and cloud computing.

Key Topics

  • Examination of the EU General Data Protection Regulation and practical implementation
  • Analysis of Data security and Privacy Global Outlook
  • Benchmark your IT approach to transformation
  • Understanding the need for Scalability and Flexibility of Cloud Computing
  • IT Infrastructure Modernisation in Pharma and Rea
  • World Implementations
  • Factors driving Digital and Mobile Technologies in Patient Engagement
  • Cloudy 2020: Cloudy Opportunities and Challenges in the future
  • Harmonization of data privacy laws across Europe
  • Discussion of pros and cons of private cloud and public cloud
  • e-commerce trends and application in Cloud

Target Audience

  • Pharmaceutical companies
  • Cloud Content Solution/Software Providers
  • Biotechnology companies
  • Medical Technology companies
  • Research Centers
  • Physicians

For further information, please visit:
http://www.inconnect.net/events/events/it-transformation-and-cloud-content-management-for-medtech-biotechnology-and-pharmaceutical-companies

About INconnect
Academic management research shows that knowledge is a crucial asset for companies concerning sustained competitive advantage. Markets provide opportunities for companies to succeed in organizing themselves around new information on industry trends and technology. Those are the companies that can and will innovate.

Improved technologies and strategies are required for innovation. The only possible fuel for innovation are ideas. Ideas arise when the right people, get the right information, in the right context.

INconnect uses its extensive international network in top-executive event management to bring together industry leaders, lawmakers and experts.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...